Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Eric Thomason

Nurse Practitioner, Psychiatric/Mental Health Pittsburg, KS Nurse Practitioner

NPI 1528425501 CMS profile 10433746

3103 N Michigan St, Pittsburg, KS 66762

Open in the dashboard

General payments

$333,405

766 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Thomason of Pittsburg, KS is reported in the CMS Open Payments database as having received $333,405 across 766 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $115,077 268
2024 General $114,607 239
2023 General $72,387 177
2022 General $31,265 76
2021 General $69 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Thomason
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Eric Thomason were reported at $115,077. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Eric Thomason Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $69 $166 $54–$482 $132
2022 $31,265 $195 $66–$559 $149
2023 $72,387 $233 $82–$673 $160
2024 $114,607 $236 $84–$688 $164
2025 $115,077 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Otsuka America Pharmaceutical, Inc. $222,232 494 payments
  2. AbbVie, Inc. $60,335 131 payments
  3. E.R. Squibb & Sons, L.L.C. $40,344 81 payments
  4. Alkermes, Inc. $5,227 25 payments
  5. Otsuka Pharmaceutical Development & Commercialization, Inc. $4,216 4 payments
  6. Lundbeck LLC $293 3 payments
  7. Axsome Therapeutics, Inc. $187 9 payments
  8. Teva Pharmaceuticals USA, Inc. $148 5 payments
  9. Novo Nordisk Inc $125 1 payment
  10. Dexcom, Inc. $123 1 payment
  11. Other $176 12 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $241,074 169 payments
  2. Consulting Fee $41,128 32 payments
  3. Travel and Lodging $40,308 263 payments
  4. Food and Beverage $10,868 301 payments
  5. Education $27 1 payment
Products named General payments · program years 2021–2025
  1. REXULTI $121,278 270 payments
  2. ABILIFY MAINTENA $91,704 197 payments
  3. ABILIFY ASIMTUFII $86,954 191 payments
  4. VRAYLAR $60,335 131 payments
  5. COBENFY $27,504 61 payments
  6. LYBALVI Cns $5,108 23 payments
  7. ABILIFY MYCITE $4,141 3 payments
  8. LYBALVI Cns $3,233 7 payments
  9. LYBALVI Cns $3,175 4 payments
  10. LYBALVI Cns $3,175 4 payments
  11. Other $9,305 116 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

663

Median for Nurse Practitioner: 389

Drug cost

$186,233

Median for Nurse Practitioner: $21,885

Branded share of claims

20.2%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 12 $94,795
Vraylar Cariprazine Hcl Brand 41 $56,524
Rexulti Brexpiprazole Brand 18 $21,713
Belsomra Suvorexant Brand 11 $4,667
Quetiapine Fumarate Er Quetiapine Fumarate Brand 15 $1,255
Buspirone Hcl Generic 68 $858
Quetiapine Fumarate Generic 26 $769
Duloxetine Hcl Generic 26 $687
Oxcarbazepine Generic 11 $564
Gabapentin Generic 40 $506

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ABILIFY MAINTENA
$27,456 — —
REXULTI
$26,601 18 —
VRAYLAR
$26,399 41 —
ABILIFY ASIMTUFII
$20,926 — —
ABILIFY MYCITE
$4,141 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

766 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record